Coagulation proteases are involved in a highly orchestrated proteolytic cascade which is essential for haemostasis and blood clotting. In particular, the initiator of the coagulation cascade, Factor VIIa, binds to its cofactor, tissue factor, and its substrate, Factor X, via exosite interactions to form a ternary catalytic complex named extrinsic Xase. These exosite interactions have also been shown to allosterically induce the active conformation of the catalytic site of Factor VIIa. We have developed a direct continuous fluorescence polarization-based extrinsic Xase assay, which has been used to screen in excess of 1 million structurally diverse low-molecular-mass compounds as a potential starting point for the development of anticoagulants. The primary screen hits were categorized with deconvolution assays into either active-site or exosite inhibitors. The latter category of hits displayed both competitive and uncompetitive modalities of inhibition with respect to Factor X activation. An uncompetitive mechanism of action is of particular interest as it offers a hypothetical inhibitory advantage in the context of inhibiting a proteolytic cascade such as the blood coagulation pathway.
Introduction
TF (tissue factor) is a membrane-bound protein not normally found in circulating plasma. Damage to the integrity of the vascular system or activation of monocytes or endothelial cells results in exposure of membrane-bound TF to the blood [1] . Subsequently, the TF exposed to the blood system will bind to small amounts of activated Factor FVII (FVIIa) already circulating in the blood system to form the TFFVIIa complex. This event initiates the coagulation cascade by further activating the zymogen form of Factor VII as well as converting downstream coagulation factors such as Factor IX and Factor X (FX) into Factor IXa and Factor Xa (FXa) respectively. The conversion of FX into FXa is considered an ideal point of intervention to block undue coagulation or thrombosis. The formation of the membrane-associated ternary complex of TF-FVIIa and FX is dependent on exosite interactions, which are allosterically regulated [2] . Therefore disruption of these exosite interactions may offer new ways of modulating FX activation in vivo as reported previously [3] .
Much progress has been made in the discovery of potent and selective inhibitors of thrombin and FXa as anticoagulant drugs, while less effort has been focused on the discovery of inhibitors of FVIIa. Recently, however, studies using anti-FVIIa antibodies, active-site-inhibited FVIIa, and recombinant anticoagulant TFPI (TF pathway inhibitor) have yielded promising results [4] . Thus there is increasing interest Key words: coagulation, exosite inhibitor, Factor VII/VIIa, Factor X/Xa, fluorescence polarization, high-throughput screening. Abbreviations used: FP, fluorescence polarization; FVIIa, Factor VIIa; FX, Factor X; FXa, Factor Xa; HTS, high-throughput screening; TF, tissue factor; TFPI, TF pathway inhibitor. 1 To whom correspondence should be addressed (email augustin.j.amour@gsk.com).
in the generation of potent and selective small-molecular FVIIa inhibitors as candidates for novel anticoagulants. This work describes the development of a continuous extrinsic Xase assay suitable for the HTS (high-throughput screening) of small-molecule active-site and exosite inhibitors of FVIIa.
A novel assay for monitoring reconstituted extrinsic Xase activity
To date, the activity of the reconstituted Xase has only been reported in indirect discontinuous measurements of the amidolytic activity of the product FXa (for example, see [5] ), which is inconvenient for HTS because of the several steps required. Discontinuous data, in addition, can present difficulties in mechanistic and kinetic interpretation.
In this article, we report the development of a continuous coupled FP (fluorescence polarization) (see [6] for a principle of FP assays) Xase assay, which has been designed using a FXa-selective reversible inhibitor coupled to a Cy3b dye (FP ligand shown in Figure 1 ). The FP ligand was found to bind FXa with a 1 nM affinity by global fitting to a quadratic equation for enzyme-ligand binding [7] and was displaced by the parent FXa inhibitor with an IC 50 of 16.5 nM (Figure 2 ) equivalent to a K d value of 2.3 nM when taking into account the ratio of concentration of FP ligand and FXa, which is in agreement with K i values measured in FXa amidolytic assays. This indicated that the affinity of the FP ligand was due solely to the inhibitor moiety of the FP ligand and not the Cy3b label itself. In addition, the association rate constant of the FP ligand binding to FXa was high and could not be measured by standard fluorescence techniques. As anticipated, the FP ligand binds only to FXa and not to either FVIIa or FX. These observations taken together indicated that the FP ligand was an ideal tool to specifically monitor activation of FX in a Xase assay. The extrinsic Xase was therefore reconstituted by mixing recombinant human proteins (FVIIa and TF) in the presence of synthetic phospholipid vesicles composed of phosphatidylcholine and phosphatidylserine, and the kinetics of FX activation were monitored with the FP ligand (Figure 3) .
The catalytic specificity constant, k cat /K m , was estimated as 6.4 × 10 9 M −1 · s −1 (k cat = 40 s −1 , K m = 6.4 nM), which is close to the theoretical diffusion rate limit of 10 10 M −1 · s
for an enzyme reaction in an aqueous buffer [8] . As a result, it was necessary to reduce the FVIIa concentration in the assay to sub-picomolar levels to enable monitoring of the progress of the reaction. A similar high association rate constant was also observed for the Xase inhibitor, TFPI [5] . These very high association rate constants are mainly due to the effect of phospholipids co-localizing the reactants over a two-dimensional surface [1] . This explanation is supported by the observation that substituting truncated soluble TF lacking the membranespanning domain into the assay reduced the association rate by five orders of magnitude (results not shown).
Identification of exosite inhibitors from HTS
The assay was miniaturized to a 5 µl assay volume in 1536-well microtitre plates and used as the basis for an HTS of GlaxoSmithKline's compound collection. The assay concentrations of FX and TF were adjusted to 12 and 1.2 nM, which were twice that of their measured equilibrium dissociation constants. This ensured that FX and TF concentrations were not saturating with respect to FX and TF, which improved our chances of identifying compounds that could disrupt their association to FVIIa. For HTS purposes, plates were read as single end points after incubation periods between 40 and 80 min and therefore the reactions were stopped with EDTA before reading plates, which gave average z' values of 0.8 (for a definition of z' values, see [9] ). However, when handling single plates, the assay was preferably read in kinetic mode, which also gave a z' value of approx. 0.8 and allowed us to detect slow-binding inhibitors. Under both assay conditions, the FVIIa-selective inhibitor PHA-927 gave K i values of ∼20 nM in agreement with those measured in TF-FVIIa amidolytic assays [4] . Compound testing further showed the assay to be sensitive to both FVIIa and FXa inhibitors, as expected, but the distinction between FVIIa and FXa inhibitors was straightforward. A direct FVIIa amidolytic assay using the quenched substrate bis(D-PhePro-Arg)-Rh110 (peptide FVIIa assay) and the assay using FXa and the FP ligand (FXa FP assay as shown in Figure 1B ) enabled us to identify FVIIa and FXa inhibitors respectively. The GlaxoSmithKline compound collection consisting of more than 1 million structurally diverse low-molecular-mass compounds was screened for potential inhibitors of the Xase FP assay. A total of 14 000 active compounds were selected for retest and, of these, 2000 were progressed to IC 50 doseresponse determinations, which were also categorized with the above deconvolution assays into either active-site or exosite inhibitors. Hits that were active in the peptide FVIIa assay were defined as active-site inhibitors, hits that were inactive in the peptide FVIIa assay were defined as exosite inhibitors, and hits that were active in the FXa FP assay were defined as false positives or non-selective inhibitors. Interestingly, exosite inhibitors behaved as either competitive or uncompetitive inhibitors with respect to the substrate FX in the Xase FP assay (Figure 4 ). Xase competitive inhibitors may bind to FVIIa exosites involved in the binding to FX [9] , while uncompetitive inhibitors may bind to sites present only in the Xase Michaelis complex. The latter may appear due to conformational changes induced by FX binding or may overlap combined FVIIa and FX sites. Uncompetitive inhibitors may offer a theoretical advantages in the context of inhibiting FX turnover owing to its very low K m (6.4 nM), while their apparent inhibition constants decrease further with increasing substrate concentration, as may be the case for FX if its turnover is inhibited and it therefore accumulates on the surface of activated platelets.
Concluding remarks
As illustrated by the interaction of FVIIa with FX, proteinases may bind protein-based substrates not just via the active site, but also via exosite interactions. Often, synthetic peptide substrates are used in HTS assays for such targets and this may preclude the discovery of exosite inhibitors, and, in addition, some active-site inhibitors if binding of the protein-based substrate induces conformational changes at the active site [10] . Exosite inhibition may offer advantages such as selectivity of inhibition with regard to closely related proteinases, since homology is frequently significant between active sites. Coagulation enzymes, for example, exhibit overlapping specificities for small peptide substrates, and it has been suggested that specificity for the endogenous substrate is to be found in those interactions which are remote from the active site. For a given proteinase that has different substrates, it may be possible to allow specific inhibition of activity against a particular substrate, which binds to the targeted exosite, over another substrate, which binds to a different exosite. We are currently undertaking biochemical and structural work to identify the sites to which our discovered exosite inhibitors bind as well as evaluating their therapeutic potential in secondary clotting assays.
